About Immunogenx
Immunogenx is a Healthcare company based in Durham (United States) founded in 2013. Solutions for treatment and management of celiac disease. The company has 6 employees. Immunogenx has completed 1 acquisition, including Alvine Pharma. Immunogenx offers products and services including Therapeutic Solution. Its focus areas include Life Sciences, Immunology, Drugs and Diversified. Its legal entity is ImmunogenX, Inc. Its competitors include Biogen, Kymeratx and PureTech Health; 3 of its 3 listed competitors have raised funding.
Company details
Immunogenx develops solutions for the treatment and management of celiac disease. Its lead therapeutic candidate is a mixture of two gluten-specific recombinant proteases that helps in the degradation of gluten proteins in order to ameliorate the symptoms of celiac disease, when it was taken in conjunction with a gluten-free diet. It is currently in phase II clinical trials. Its lead diagnostic candidate CypCel is a metabolic assay. The patient is given a dose of the widely-used statin drug simvastatin, and the subsequent serum level of simvastatin is measured as a marker for the health of intestinal epithelium.
- Headquarters Durham, United States
- Employees 6
- SectorsHealthcare
- Website immunogenx.com
- Social LinkedIn
- Legal Name Immunogenx, Inc.
- Latest Funding Round$2.2M (USD), Grant
Sep 2020
- Investors
- Employee Count6
- Investments & Acquisitions
Products & Services of Immunogenx
Immunogenx offers a comprehensive portfolio of products and services, including Therapeutic Solution.
Develops therapies to address gluten-free diet challenges for celiac disease patients.
Funding Insights of Immunogenx
- Total Rounds 2
- Last Round Grant — $2.2M
- First Round $874,356
(Sep 2017)
- Investors Count 1
All 2 funding rounds of Immunogenx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in Immunogenx
Immunogenx has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Immunogenx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Immunogenx
10 people are tracked at Immunogenx (3 in leadership, 7 in board & advisors); the tracked headcount is 6.
| Name | Role | Group |
|---|---|---|
Jack A. Syage | CEO & Co-Founder | Leadership |
Matthew Dickason | COO | Leadership |
Jennifer Sealey-Voyksner | CSO & Co-Founder | Leadership |
Joseph A. Murray | Scientific Advisor | Board & advisors |
Ciarán P. Kelly | Director | Board & advisors |
Jack Henion | Director | Board & advisors |
Chaitan Khosla | Director | Board & advisors |
Janice Soreth | Director | Board & advisors |
Peter H. R. Green | Scientific Advisor | Board & advisors |
Markku Mäki | Director | Board & advisors |
Complete people profiles for Immunogenx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Immunogenx
Immunogenx has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Alvine Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developing therapeutics for autoimmune and inflammatory diseases. | alvinepharma.com | San Carlos, United States | 2005 | Mar 2016 | •••• |
Complete acquisition details for Immunogenx
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Immunogenx
4 dated milestones of Immunogenx across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Immunogenx is founded.
- Acquisition Acquires Alvine Pharma.
- Funding First funding round of $874K.
- Funding Latest funding round, Grant, of $2.2M.
Competitors of Immunogenx
Immunogenx has 3 listed competitors in our database, 3 of them funded. They include Biogen, Kymeratx and PureTech Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. |
Detailed competitors of Immunogenx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Immunogenx (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Immunogenx
Complete news archive for Immunogenx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immunogenx
Immunogenx was founded in 2013 and raised its 1st funding round 4 years after it was founded.
Immunogenx is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Immunogenx has 6 employees.
Immunogenx develops solutions for the treatment and management of celiac disease. Its lead therapeutic candidate is a mixture of two gluten-specific recombinant proteases that helps in the degradation of gluten proteins in order to ameliorate the symptoms of celiac disease, when it was taken in conjunction with a gluten-free diet. It is currently in phase II clinical trials. Its lead diagnostic candidate CypCel is a metabolic assay. The patient is given a dose of the widely-used statin drug simvastatin, and the subsequent serum level of simvastatin is measured as a marker for the health of intestinal epithelium.
Immunogenx's top competitors include Kymeratx, PureTech Health and Biogen.
Immunogenx offers Therapeutic Solution.
Immunogenx has made 1 acquisition, including Alvine Pharma.
Immunogenx has 1 investor. Key investors include HHS.
Immunogenx operates through Immunogenx, Inc..